Product: VeriStrat
-
Serum mass-spectrometry test in first line advanced NSCLC patients treated with standard chemotherapy regimens
-
Efficacy analysis of gefitinib +/- ficlatuzumab in serum proteomic-based subgroups of patients with previously untreated lung adenocarcinoma
-
Tissue biomarker analysis in PROSE, a randomized proteomic stratified phase III study of second line erlotinib (E) versus chemotherapy (CT) in patients with inoperable non-small cell lung cancer (NSCLC)
-
Serum and Tumor Biomarkers Predict Outcome in the eLung Trial, a Multicenter, Randomized Phase IIb Study of Standard Platinum Doublets plus Cetuximab as First-line Treatment of Advanced Non-Small Cell Lung Cancer
-
Assessment of the association of the VeriStrat test with outcomes in patients (pts) with advanced pancreatic cancer (PC) treated with gemcitabine (G) with or without erlotinib (E) in the NCIC CTG PA.3 phase III trial.
-
A Retrospective Analysis of VeriStrat Status on Outcome of a Randomized Phase II Trial of First-Line Therapy with Gemcitabine, Erlotinib, or the Combination in Elderly Patients (Age 70 Years or Older) with Stage IIB/IV Non–Small-Cell Lung Cancer
-
The impact of a serum based proteomic mass spectrometry test on treatment recommendations in advanced non-small-cell lung cancer
-
A phase II study of bevacizumab and erlotinib as initial treatment for metastatic non-squamous, non-small cell lung cancer with serum proteomic evaluation
-
A Phase II Study of Sorafenib in Patients with Platinum-Pretreated, Advanced (Stage IIIb or IV) Non–Small Cell Lung Cancer with a KRAS Mutation
-
VeriStrat has a prognostic value for patients with advanced non-small cell lung cancer treated with erlotinib and bevacizumab in the first line: Pooled analysis of SAKK19/05 and NTR528